Robust validation in preclinical studies suggests potent clinical efficacy.
Engineered SRC-3 KO Treg cells have been
stress tested in various conditions:
-
Studied in a broad range of aggressive solid tumors
-
Effective in preventing growth of tumors
-
Effective in eradicating established tumors
-
Dose response studies further validate therapy
Proven effective in preclinical models.
We’ve conducted tests in over 400+ tumor-bearing mice and the results are astonishing. CoRegen engineered Tregs permanently eradicated and prevented cancer without toxicity or inflammation in the following mouse models:
Triple Negative Breast Cancer
U.S. 44K new case per year
Prostate Cancer
U.S. 288K new case per year
Pancreatic Cancer
U.S. 64K new case per year
Colorectal Cancer
U.S. 152K new case per year
Glioblastoma
U.S. 14K new case per year
Non-Small Cell Lung Cancer
U.S. 238K new case per year
Impressive and consistent preclinical efficacy.
Pre-clinical immune studies in mice commonly align with human clinical trial outcomes.
Eradication of aggressive cancer cells
No cancer recurrence
Does not lead to immune related adverse events
Non-toxic and no inflammation
No off-target effects
Rapid treatment results
Normal animal reproduction
Live full lifespan